This hypothesis was further supported by a subsequent study by Meyer et al. [39], which confirmed that MTAP-positive melanomas derive significant survival benefit from adjuvant interferon, whereas MTAP-negative tumors show no therapeutic response. The gene discussed is MTAP; the disease is melanoma.